 Heres a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks Biotech stocks hitting 52-week highs May 5. Arcturus Therapeutics Ltd NASDAQ: ARCT announced a partnership with Catalent Inc NYSE: CTLT for manufacturing of a vaccine against the novel coronavirus BIO-TECHNE Corp NASDAQ: TECH Bio-Rad Laboratories, Inc. Class A Common Stock NYSE: BIO ChemoCentryx Inc NASDAQ: CCXI DexCom, Inc. NASDAQ: DXCM received Health Canada temporary authorization for its Dexcom G6 CGM for use in hospitals to monitor critically ill patients during COVID-19 pandemic Halozyme Therapeutics, Inc. NASDAQ: HALO announced FDA approval for Johnson Johnson NYSE: JNJ Janssen units subcutaneous formulation of Darzalex, which uses Halozymes Enhanze technology, in treating multiple myeloma Imara Inc NASDAQ: IMRA Immunomedics, Inc. NASDAQ: IMMU announced the commercial availability of its recently-approved breast cancer drug Trodelvy in the U.S. Masimo Corporation NASDAQ: MASI Minerva Neurosciences Inc NASDAQ: NERV Vermillion, Inc. NASDAQ: VRML Zynex Inc. NASDAQ: ZYXINone of the biotechmedical devicesdiagnostics company hit 52-week lows Monday.Stocks In Focus Adverums Gene Therapy Shows Robust Efficacy, Safety In Phase 1 Study For Wet Age-Related Macular Degeneration Adverum Biotechnologies Inc NASDAQ: ADVM announced new interim clinical data from Cohorts 1-3 of the OPTIC Phase 1 dose-ranging clinical study of single-dose of ADVM-022 intravitreal injection gene therapy in patients with wet age-related macular degeneration, which further demonstrated the transformative potential of ADVM-022 to greatly reduce anti-VEGF injection burden in wet AMD.Its impressive to see the long-term durability demonstrated at the higher dose of ADVM-022 in a patient population that previously required frequent injections to maintain their vision and are now beyond one year of follow-up with no rescue injections, Arshad Khanani, the studys principal investigator, said in a statement.The company also offered a business update, reporting cash, cash equivalents and short-term investments of 297 million as of March 31. Adverum said it expects to submit a NDA for ADVM-022 in diabetic retinopathy in the first half of 2020 and present data from all four cohorts of the OPTIC trial in the second half.Bio-Rad Droplet Digital PCR Test Kit For Coronavirus Receives EUA Bio-Rad said its SARS-CoV-2 Droplet Digital PCR test kit has been granted Emergency Use Authorization by the FDA. The SARS-CoV-2 Droplet Digital PCR test runs on Bio-Rads QX200 and QXDx ddPCR systems.Chembios Serological Test For Coronavirus Gets CE Marking Chembio Diagnostics Inc NASDAQ: CEMI said it has attained the CE Marking for its DPP COVID-19 System. The CE Marking allows the company commercialize the system within the member states of the European Union and the Caribbean region, except for Puerto Rico.The DPP COVID-19 System is a serological test and analyzer that provides numerical readings for both IgM and IgG antibody levels within 15 minutes from a simple finger stick drop of blood. The test has received EUA in the U.S.Separately, the company reported first-quarter results, showing a 20 decline in revenue to 6.9 million and a wider net loss of 29 cents per share.In premarket trading Tuesday, the stock was gaining 17.47 to 14.39.View more earnings on IBBSee also: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates Regeneron, Sanofi Say PD-1 Inhibitor Libtayo Found Effective In Skin Cancer In Pivotal Study Regeneron Pharmaceuticals Inc NASDAQ: REGN and Sanofi SA NASDAQ: SNY announced top-line data from a pivotal, single-arm, open-label trial of PD-1 inhibitor Libtayo in patients with advanced basal cell carcinoma who had progressed on or were intolerant to prior hedgehog pathway inhibitor therapy. The data showed the investigational asset demonstrated clinically meaningful and durable responses in this group of patients for whom there are currently no approved treatments.The companies said they plan regulatory submissions in 2020.Libtayo was approved in September 2018 by the FDA to treat patients with metastatic cutaneous squamous cell carcinoma.Insmed Announces Secondary Offering Of Common Stock Insmed Incorporated NASDAQ: INSM said it intends to offer and sell shares of its common stock in an underwritten public offering. All the shares are being offered by the company.The stock was down 0.84 at 24.65 in Tuesdays premarket session.Earnings GenMark Diagnostics, Inc NASDAQ: GNMK announced first-quarter revenue of 38.7 million, in line with the number it mentioned in its April 8 pre-announcement and representing an 80 year-over-year increase. The loss per share narrowed from 21 cents to 12 cents, while analysts estimated a loss of 14 cents per share.The company raised its full-year revenue guidance to 120 million to 130 million, ahead of the 108.58-million consensus estimate, and it also increased its gross margin guidance to 38-40.Separately, GenMark announced the appointment of Scott Mendel as CEO. Mendel has been serving as CEO on an interim basis since February.The stock was up 13.29 at 13.30 in the premarket session.On The Radar Earnings Oxford Immunotec Global PLC NASDAQ: OXFD before the market open Karyopharm Therapeutics Inc NASDAQ: KPTI before the market open Haemonetics Corporation NYSE: HAE before the market open Antares Pharma Inc NASDAQ: ATRS before the market open Harvard Bioscience, Inc. NASDAQ: HBIO before the market open Vericel Corp NASDAQ: VCEL before the market open Regeneron Neuronetics Inc NASDAQ: STIM before the market open Mallinckrodt PLC NYSE: MNK before the market open Akebia Therapeutics Inc NASDAQ: AKBA before the market open Agile Therapeutics Inc NASDAQ: AGRX after the market close Aquestive Therapeutics Inc NASDAQ: AQST after the market close Akcea Therapeutics Inc NASDAQ: AKCA after the market close Acorda Therapeutics Inc NASDAQ: ACOR after the market close Axonics Modulation Technologies Inc NASDAQ: AXNX after the market close Synthetic Biologics Inc NYSE: SYN after the market close T2 Biosystems Inc NASDAQ: TTOO after the market close Iovance Biotherapeutics Inc NASDAQ: IOVA after the market close MacroGenics Inc NASDAQ: MGNX after the market close Zogenix, Inc. NASDAQ: ZGNX after the market close Jazz Pharmaceuticals PLC NASDAQ: JAZZ after the market close Exelixis, Inc. NASDAQ: EXEL after the market close Myriad Genetics, Inc. NASDAQ: MYGN after the market close Inspire Medical Systems Inc NYSE: INSP after the market close Rigel Pharmaceuticals, Inc. NASDAQ: RIGL after the market close Supernus Pharmaceuticals Inc NASDAQ: SUPN after the market close Nevro Corp NYSE: NVRO after the market close Clovis Oncology Inc NASDAQ: CLVS after the market close InVitae Corp NYSE: NVTA after the market close Cytosorbents Corp NASDAQ: CTSO after the market close Cardiovascular Systems Inc NASDAQ: CSII after the market close Cerus Corporation NASDAQ: CERS after the market close Deciphera Pharmaceuticals Inc NASDAQ: DCPH after the market close Incyte Corporation NASDAQ: INCY after the market close Orthopediatrics Corp NASDAQ: KIDS after the market closeRelated Link: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace See more from Benzinga The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPOC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 